Results 211 to 220 of about 98,994 (359)

Diagnostic Utility of PRAME Immunohistochemistry for Distinguishing Acral Melanoma From Acral Melanocytic Nevi

open access: yesJournal of Cutaneous Pathology, EarlyView.
ABSTRACT Introduction Preferentially expressed antigen in melanoma (PRAME) immunohistochemistry helps distinguish non‐acral melanocytic lesions, but few studies have addressed its value in acral lesions. We aimed to identify an optimal PRAME cut‐off score to differentiate acral melanoma (AM) from acral melanocytic nevi (AMN).
Kritsada Phatcharamaneepakorn   +4 more
wiley   +1 more source

Cutaneous Melanoma in the Context of Aging. [PDF]

open access: yesMedicina (Kaunas)
Neagu M, Constantin C, Zurac S.
europepmc   +1 more source

Prognostic Significance of Nuclear ING3 Expression in Human Cutaneous Melanoma [PDF]

open access: bronze, 2007
Yemin Wang   +3 more
openalex   +1 more source

Cytology‐First Diagnostic Workflow for Melanoma of Unknown Primary With Molecular Profiling

open access: yesCytopathology, EarlyView.
Cytology‑first diagnostic workflow for melanoma of unknown primary. Fine‑needle aspiration of an enlarged lymph node enables rapid cytologic evaluation and immunocytochemical confirmation of melanocytic lineage (SOX10). This early cytologic diagnosis facilitates timely surgical excision and comprehensive genomic profiling, supporting integrated ...
Hong Yu   +3 more
wiley   +1 more source

Hypothyroidism as Prognostic Factor in Cutaneous Melanoma: A 1553-Patient Single-Center Study. [PDF]

open access: yesCancer Med
Klose J   +8 more
europepmc   +1 more source

Supplementary Data from Dual Covalent Inhibition of PKM and IMPDH Targets Metabolism in Cutaneous Metastatic Melanoma

open access: gold, 2023
Marwa Zerhouni   +22 more
openalex   +1 more source

Association Between Blood Transfusion and Survival Outcomes in Metastatic Cutaneous Melanoma Treated with Nivolumab. [PDF]

open access: yesCancer Manag Res
Coskun A   +8 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy